Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin‐deficient mice

FEBS Letters - Tập 584 - Trang 2403-2408 - 2010
Christopher Lipina1, Hannah Kendall1, Alexandra C. McPherron2, Peter M. Taylor1, Harinder S. Hundal1
1Division of Molecular Physiology, Sir James Black Centre, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom
2Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA

Tóm tắt

Myostatin deficiency leads to both an increased rate of protein synthesis and skeletal muscle hypertrophy. However, the mechanisms involved in mediating these effects are not yet fully understood. Here, we demonstrate that genetic loss of myostatin leads to enhanced muscle expression of both protein kinase B and mammalian target of rapamycin/S6K signalling components, consistent with their elevated activity. This is associated with a reduction in the expression of PGC1α and COX IV, proteins which play important roles in maintaining mitochondrial function. Furthermore, we show that these changes in signalling and protein expression are largely independent of alterations in intramuscular amino acid content. Our findings, therefore, reveal potential new mechanisms and further contribute to our understanding of myostatin‐regulated skeletal muscle growth and function.


Tài liệu tham khảo

10.1016/0022-510X(88)90132-3 10.1016/S0899-9007(00)00407-X 10.1097/00000658-200101000-00003 10.1016/j.pharmthera.2006.11.004 10.1101/gr.7.9.910 10.1038/387083a0 10.1073/pnas.94.23.12457 10.1016/j.tig.2007.08.008 10.1073/pnas.151270098 10.1152/ajpendo.2001.280.2.E221 10.1074/jbc.M204291200 10.1016/S0014-4827(03)00074-0 10.1210/en.2003-1166 10.1073/pnas.0505996102 10.1038/84839 10.1038/ncb1101-1009 10.1038/ncb1101-1014 10.1002/jcp.20757 10.1210/en.2008-0959 10.1152/ajpcell.00104.2009 10.1152/ajpcell.00105.2009 10.2337/diabetes.52.3.642 10.1038/nature06322 10.1101/gad.454408 10.2337/diabetes.47.7.1006 10.1113/jphysiol.2008.159830 10.1128/MCB.24.21.9295-9304.2004 10.1038/ng0997-71 10.1016/S0006-291X(02)02953-4 10.1152/ajpendo.90862.2008 10.1152/ajpcell.00043.2009 10.1016/S0014-5793(99)00193-3 10.1093/emboj/cdg240 10.1158/0008-5472.CAN-05-3060 10.1002/mus.10160 10.1096/fj.05-5125fje 10.1210/en.2006-0539 10.1007/s00424-008-0499-0 10.1038/onc.2009.401 10.1038/ncb839 10.1074/jbc.M210837200 10.1371/journal.pone.0001217 10.1038/ncb1547 10.1016/S0092-8674(04)00400-3 10.1210/jc.86.5.2136 10.1152/ajpendo.00430.2003 10.1152/ajpendo.00609.2006 10.1371/journal.pone.0004937 10.1007/s00726-007-0573-5 10.1016/0005-2728(96)00077-1 10.1152/jappl.1997.83.1.166 10.1111/j.1475-097X.1982.tb00001.x 10.1172/JCI0213562 10.1002/mus.20175 10.1186/1471-2164-10-196 10.1186/1471-213X-9-24 10.1096/fasebj.13.14.2051 10.1152/ajpregu.00396.2007 10.1210/jc.2003-032047 10.1089/rej.2007.0588 10.2337/db08-0943 10.1007/s00018-008-8077-3 10.1038/ijo.2009.162